Literature DB >> 9284572

[Immunohistochemical characteristics of mammary carcinomas with estrogen-negative and progesterone-positive receptors].

A S Sundblad1, L Caprarulo.   

Abstract

In a series of 256 mammary carcinomas, 22 (8.5%) were positive for progesterone receptors (PR) and negative for estrogen receptors (ER). These cases seem to belong to a distinctive group with a biologic behavior not well understood. In order to contribute to a better understanding of such tumors, their association with different pathologic and immunohistochemical factors were compared with those of the rest of the tumors of the series. The results were that favorable factors such as smaller size, negative axillary lymph nodes and low histologic and nuclear grades were decreasingly associated with tumors that were ER+ PR+; ER+ PR-; ER- PR+; and ER- PR-. In relation to immunohistochemical features, tumors that were ER+ PR+; ER+ PR- and ER- PR+ behaved in a similar way, whereas ER- PR- tumors were different from the rest because fewer expressed bcl-2 (p = 0.0000) and had a greater expression for p53 (p = 0.009) and MIB-1/Ki-67 (p = 0.05). No significant differences were found between the four populations in recurrence rate or metastases, nor overall survival. In conclusion, these findings show that tumors that are ER- PR+ might have biological characteristics somewhere in between ER+ PR+ and ER- PR+.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9284572

Source DB:  PubMed          Journal:  Medicina (B Aires)        ISSN: 0025-7680            Impact factor:   0.653


  2 in total

1.  Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.

Authors:  Soo Youn Bae; Sangmin Kim; Jun Ho Lee; Hyun-Chul Lee; Se Kyung Lee; Won Ho Kil; Seok Won Kim; Jeong Eon Lee; Seok Jin Nam
Journal:  BMC Cancer       Date:  2015-03-18       Impact factor: 4.430

Review 2.  Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes.

Authors:  Xiaofeng Dai; Liangjian Xiang; Ting Li; Zhonghu Bai
Journal:  J Cancer       Date:  2016-06-23       Impact factor: 4.207

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.